ESR1 and triple-negative breast carcinoma: Importantly, lovastatin inhibits cell proliferation and migration in both ER positive and triple negative breast cancer cells, possibly due to a decrease in intracellular cholesterol levels [39], and cholesterol is able to rescue these effects of lovastatin.